氟哌噻吨美利曲辛对胃食管反流患者睡眠质量和躯体化症状的影响

Effects of Flupentixol Melitracine on Sleep Quality and Somatization Symptoms in Patients with Gastroesophageal Reflux

目的:探讨氟哌噻吨美利曲辛治疗胃食管反流伴睡眠障碍和躯体化症状的临床效果。方法:选取2019年8月至2020年7月新疆医科大学第五附属医院收治的胃食管反流伴睡眠障碍和躯体化症状患者78例作为研究对象,按照随机数字表法随机分为对照组和观察组,每组39例。对照组给予促胃肠动力药物和胃黏膜保护剂等常规治疗,观察组在对照组治疗基础上给予氟哌噻吨美利曲辛治疗,2组疗程均为8周。比较2组患者的临床治疗效果、胃食管反流病问卷(RDQ)评分、匹兹堡睡眠质量指数(PSQI)量表评分、抑郁自评量表(SDS)评分、焦虑自评量表(SAS)评分和不良反应发生率。结果:1)疗程后,观察组的临床治疗总有效率为94.9%,明显高于对照组的临床治疗总有效率为69.2%(P<0.05);2)治疗前,2组患者的RDQ评分、PSQI评分、SDS和SAS评分比较,差异均无统计学意义(均p>0.05),治疗后,2组患者的RDQ评分、PSQI评分、SDS和SAS评分显著低于治疗前(P<0.05),且观察组低于对照组(P<0.05);3)2组患者的治疗不良反应发生率比较,差异无统计学意义(P>0.05)。结论:氟哌噻吨美利曲辛能够更有效地改善胃食管反流患者的躯体化症状,缓解患者的负性情绪,改善患者的睡眠质量,且安全性较高,值得在临床上推广应用。

Objective:To investigate the clinical effect of flupentixol melitracine in the treatment of gastroesophageal reflux patients with sleep disorders and somatization symptoms.Methods:A total of 78 patients with GASTROesophageal reflux with sleep disturbance and somatization symptoms admitted to the Fifth Affiliated Hospital of Xinjiang Medical University from August 2019 to July 2020 were selected as the research objects,and randomly divided into control group and observation group according to the numerical method,with 39 cases in each group.The control group was given routine treatment such as gastrointestinal motility promoting drugs and gastric mucosal protective agents,and the observation group was given flupentixol melitaxine on the basis of the control group.The courses of both groups were 8 weeks.Clinical efficacy,GASTROesophageal reflux disease questionnaire(RDQ)score,Pittsburgh Sleep Quality Index(PSQI)score,self-rating Depression Scale(SDS)score,self-rating Anxiety Scale(SAS)score and incidence of adverse reactions were compared between 2 groups.Results:1)After the course of treatment,the total effective rate of the observation group was 94.9%,which was significantly higher than that of the control group(69.2%)(P<0.05).2)Before treatment,there were no significant differences in RDQ score,PSQI score,SDS and SAS score between 2 groups(P>0.05).After treatment,RDQ score,PSQI score,SDS and SAS score between 2 groups were significantly lower than before treatment(P<0.05),and the observation group was lower than the control group(P<0.05).3)There was no significant difference in the incidence of adverse reactions between 2 groups(P>0.05).Conclusion:Flupentixol melitracine can effectively improve somatization symptoms,relieve negative emotions and improve sleep quality in patients with GERD,with high safety and worthy of further promotion in clinical practice.